HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Papaioannou, S. Articles by Cochrane, G. W Search for Related Content PubMed Articles by Papaioannou, S. Articles by Cochrane, G. W

Selective oestrogen receptor modulators: an update

Assisted Conception Unit, Birmingham Women's Hospital, Metchley Park Road, Birmingham, B15 2TG, UK. email: spyrospap{at}talk21.com

David W Purdie, MD FRCP Ed FRCOG, Consultant

Centre for Metabolic Bone Disease, HS Brocklehurst Building, Hull Royal Infirmary, Hull, HU3 2RW, UK.

Geoffrey W Cochrane, FRCOG, Consultant Obstetrician and Gynaecologist

King George Hospital, Barley Lane, Goodmayes, Essex, IG3 8YB, UK.

This paper discusses new developments in the area of selective oestrogen receptor modulators and more specifically raloxifene. The most exciting of these developments is the observed reduction in the risk of breast cancer in postmenopausal women on raloxifene therapy. The license of the product has now been extended to cover treatment as well as prevention of osteoporosis. Furthermore, raloxifene appears to have a positive impact on the serum lipid profile and there are continuing trials investigating whether these changes translate to a reduction in cardiovascular morbidity and mortality.

Keywords Keywords / hormone replacement therapy (HRT) / menopause / raloxifene / selective oestrogen receptor modulators (SERMS) / tamoxifen